Asieris Pharmaceuticals focuses on the development of novel anti-cancer and anti-multidrug resistance infection drugs with high market potentials and unmet needs in the clinical through internal research and collaboration. Meanwhile, we leverage our leading position in the field of urological oncology to selectively in-license products from foreign companies for co-developing the market in China.
